Standigm

Exciting Webinar Alert! 💡 Join us on September 26, 2024, for an exciting webinar: "AI meets Chemistry: Standigm’s Breakthrough with Merck Group Synthia™ Retrosynthesis Software." What You’ll Learn: 1. How Standigm uses Synthia™ tools to speed up drug discovery. 2. The role of AI in revolutionizing pharmaceutical research. 3. Insights from top experts in chemistry, biology, and AI. Speakers: Ewa Gajewska, Head of Product Management at Merck KGaA. 송유영 (You Young Song), Principal AI Scientist at Standigm. Date: September 26, 2024 Time: 09:00 BST, 10:00 CEST, 17:00 KST Registration: https://lnkd.in/g96mJ8-q Register now and dive into the future of drug discovery! #Webinar #AI #DrugDiscovery #Innovation #Synthia #Standigm #Healthcare

Meet AI Drug Discovery SaaS with Standigm! Standigm AI drug discovery SaaS enables faster drug discovery through partnerships. Here’s how you can speed up your science with a simple API integration: 1. STELLA: AI-Driven Hit-to-Lead MPO (Multi-Parameter Optimization) MPO powered by genetic algorithms and advanced AI algorithm, speeding up hit-to-lead optimization. 2. SPICA: AI-Powered Novelty Assessment Instantly receive a novelty score, transforming hours of analysis into mere seconds. Advanced similarity and summaries of related patent. 3. QIP-ADMET: Predictable ADMET Properties Comprehensive property predictions: Offers reliable predictions for absorption, distribution, metabolism, excretion, and toxicity (ADMET). If you are interested in trying out, contact us for a quicker drug discovery! 💡🔬 #AI #DrugDiscovery #Biotechnology #Pharmaceuticals #Standigm

🚀 Exciting News from Standigm! 🚀 We're thrilled to announce that our latest research paper, "Quantum-Informed Molecular Representation Learning Enhancing ADMET Property Prediction," has been accepted and published by the Journal of Chemical Information and Modeling! In this study, we leveraged advanced graph transformers and quantum chemistry simulations to significantly improve the prediction of ADMET properties. Our innovative pretraining strategy outperforms conventional methods, achieving state-of-the-art results in multiple ADMET tasks. Check out the full paper to read about our approach and findings: #Innovation #Research #ADMET #MolecularRepresentation #MachineLearning #QuantumChemistry #Standigm

Standigm is revolutionizing the pharmaceutical industry by significantly reducing the time and cost required for drug development.   Standigm uses AI to optimize the entire drug development process. Our CEO Sang Ok Song highlights Standigm's competitive advantage in the growing competition and advancements in AI drug discovery, showcasing the potential to streamline the development of new therapeutics.   For more details, you can read the full article (in Korean) below:

Standigm will be exhibiting at BIO International Convention. For those interested in our technology, please visit our Booth (#5407) in the Korea Pavilion. At the booth, our CEO Sang Ok Song and CBO Carl Foster will introduce you to our platform and services Standigm ASK-LLM, STELLA, ADMET, and SPICA and demonstrate them with our trial program. To connect, please send us a meeting request through partnering program. For more information about our technology please visit: www.standigm.com #BIOInternational2024 #BIOInternationalCovention #Standigm #AIdrugdiscovery #KoreaPavilion

Standigm's CEO Sang Ok Song has shared his insights on Generative and Predictive AI in drug discovery at Bio Korea Conference. For those who missed Sang Ok's session, you can find his presentation from below link: https://lnkd.in/gSthGi2E If you want to learn more about our technology, please contact us at business@standigm.com

Standigm's CEO Sang Ok Song will be presenting about "Generative and Predictive AI in Drug Discovery" as panel in #2024BIOKorea For those of you interested in AI Drug Discovery, please join the conference on May 9th 2024 at 13:30 - 16:30 COEX 3F Conference Hall. You can reach Standigm team at www.standigm.com or business@standigm.com

Standigm's CEO Sang Ok Song will be presenting about "Generative and Predictive AI in Drug Discovery" as panel in #2024BIOKOREA For those of you interested in AI Drug Discovery, please visit BIO Korea, especially Session 4, to learn more about the topic and Standigm's technology. To learn more about Standigm's platform and collaboration opportunities, please set up a meeting with Sang Ok and Standigm's scientists Hyungjin and Youngkwan from the partnering sessions. For more information about BIO Korea, please visit: https://lnkd.in/gQE8M2b You can reach Standigm team at www.standigm.com or business@standigm.com

Standigm has been featured in Forbes Korea's "2024 Korea AI 50" that highlights AI companies leading the industry. Standigm provides end-to-end solutions ranging from discovery to active material exploration, material optimization, and derivation of preclinical candidate materials. In the industry, the average time it took to optimize materials was about 4.5 years, but using the platform, it was reduced to 1.5 years, which is considered groundbreaking. For more information about leading AI companies in Korea please visit the following link: https://lnkd.in/gu2268Y6

Standigm has been featured on an article as one of the notable company that actively employs artificial intelligence in the pharmaceutical industry. The article introduces the direction in which AI will change the paradigm of the pharmaceutical industry based on research conducted by National Research Foundation of Korea. To access the full article please visit the following link: https://lnkd.in/ghrdawrU